Business Wire

Semifinalist Teams Selected in $10M ANA Avatar XPRIZE Competition

5.4.2021 18:00:00 EEST | Business Wire | Press release

Share

XPRIZE, the world’s leader in designing and operating incentive competitions to solve humanity’s grand challenges, announced today that 38 teams from 16 countries are advancing to the semifinals round of the $10M ANA Avatar XPRIZE competition.

Sponsored by All Nippon Airways (ANA), Japan’s largest airline, the Avatar XPRIZE is a four-year global competition focused on the development of an avatar system that will deploy a human’s senses, actions, and presence to a remote location in real time, leading to a more connected world. These avatars must demonstrate the ability to execute tasks across a variety of real-world scenarios and convey a sense of presence for both the operator and the recipient in those interactions. In the future, avatars could help provide critical care and deploy immediate responses in emergency situations, or offer opportunities for exploration and new ways of collaboration, stretching the boundaries of what is possible and maximizing the impact of skill and knowledge sharing.

“We are rapidly approaching an era where it will be possible for a doctor in New York to export their skillset virtually to respond to a natural disaster across the globe,” said Anousheh Ansari, CEO of XPRIZE. “The task at hand for these incredible semifinalist teams competing in the ANA Avatar XPRIZE is to break through physical limitations and expand the capacity of humankind itself through transformative robotic avatar technology.”

In February 2021, qualified teams completed their semifinalist selection submissions—the second round of technical submissions for evaluation by the judging panel. Each team submitted a comprehensive write-up detailing their avatar system's capabilities and their development plans, accompanied by a demonstration video showcasing their technology in action. The judges extensively reviewed the submissions and selected 38 semifinalists to advance out of the field of 77 qualified teams.

The ANA Avatar XPRIZE semifinalist teams are:

  • 1to1Robotics, Hackensack, New Jersey, United States
  • Aham, Bangalore, India
  • Augnition, Helsinki, Finland
  • AvaDynamics, Pittsburgh, Pennsylvania, United States
  • Avatar Quest, San Jose, California, United States
  • AVATRINA, Urbana, Illinois, United States
  • BellContinuous, Arlington, Texas, United States
  • Cyberselves, Sheffield, United Kingdom
  • Dragon Tree Labs, Moscow, Russia
  • ENZO AVATAR, Bucaramanga, Colombia
  • Forged Droids, Tempe, Arizona, United States
  • GITAI, Tokyo, Japan
  • H2L, Tokyo, Japan
  • Human Fusions, Cleveland, Ohio, United States
  • i-Botics, Utrecht, Netherlands
  • iCub, Genoa, Italy
  • Inbiodroid, Irapuato, Mexico
  • Janus, Tsukuba, Japan
  • Junnichi Suko, Tokyo, Japan
  • Kimaera Dynamics, Toronto, Canada
  • Last Mile – small world project 2, Osaka, Japan
  • Limitless, Lugano, Switzerland
  • NimbRo, Bonn, Germany
  • Pollen Robotics, Bordeaux, France
  • proRobot, Vysoké Mýto, Czech Republic
  • Rezilient, St. Louis, Missouri, United States
  • Robot Guru (HoloSuit), Mysuru, India
  • Robotics Services LLC, Providence, Rhode Island, United States
  • Roboy, Munich, Germany
  • Sant'Anna, Pisa, Italy
  • SYNAPSE, Tokyo, Japan
  • Team Northeastern, Boston, Massachusetts, United States
  • Team SNU, Ulsan, South Korea
  • Team UNIST, Seoul, South Korea
  • Telexistence, Tokyo, Japan
  • Touchlab, Edinburgh, United Kingdom
  • Virtual Sapiens, Chennai, India
  • X-Presence, Kobe, Japan

Additional details about all competing teams can be found here.

“The breakthroughs that will develop out of the ANA Avatar XPRIZE have the potential to entirely reimagine the human experience,” said David Locke, Executive Prize Director of ANA Avatar XPRIZE. "We’re thrilled to announce the semifinalist teams and are excited to put their technologies to the test, and experience their ability to transport our sense of presence, during semifinals testing this fall.”

"Now that the semifinalist teams have been chosen, we are one very important step closer to realizing our dream of revolutionizing human connection," said Mitsuo Tomita, Senior Vice President of Marketing at All Nippon Airways. "As a company whose mission it is to connect people, we are beyond excited to see the technology that will be developed by these 38 teams. We are eager to see the innovative ways in which the teams will light up our imaginations with visions of a future in which travel and human connection are limitless."

After the completion of semifinals testing in Fall 2021, up to 20 teams will equally split a Semifinals prize purse of $2M and move on to finals testing in Summer 2022. There, they will compete to win a share of the $8M finals prize purse.

The grand prize will be awarded in June 2022 after finals testing, which will include performance tests based on specific tasks that showcase the application of avatar technologies across several use case scenarios. The winning team will integrate multiple emerging technologies to develop a physical, nonautonomous avatar system with which an operator can see, hear, and interact within a remote environment in a manner that feels as if they are truly there.

The ANA Avatar Advisory Board has been integral in the competition since its launch in January 2019. The group consists of esteemed robotics experts, haptics inventors, psychology professors, top entertainment researchers, virtual world creators, computer vision dynamos and more. The full list of experts can be found below with additional information and bios available here.

For more information on the ANA Avatar XPRIZE, the semifinalist teams, and ANA, please visit avatar.xprize.org.

About XPRIZE

XPRIZE, a 501(c)(3) nonprofit organization, is the global leader in designing and implementing innovative competition models to solve the world’s grandest challenges. Active competitions include the $100 Million XPRIZE Carbon Removal with Elon Musk, $20 Million NRG COSIA Carbon XPRIZE, $15 Million XPRIZE Feed the Next Billion, $10 Million XPRIZE Rainforest, $10 Million ANA Avatar XPRIZE, $5 Million IBM Watson AI XPRIZE, $5 Million XPRIZE Rapid Reskilling and $1M Digital Learning Challenge. For more information, visit xprize.org.

ABOUT ANA

Founded more than 60 years ago in 1952 with just two helicopters, All Nippon Airways (ANA), has become the largest airline in Japan, serving 46 international destinations and 50 domestic destinations.

ANA HOLDINGS Inc. (ANAHD) was established in 2013 as the largest airline group holding company in Japan comprised of 78 companies including ANA and Peach Aviation Limited, the leading LCC in Japan. The 78 companies organized under the ANAHD umbrella operate in a diverse range of markets, including air transportation, travel services and trade, and retail embody ANAHD’s shared values of exceptional service, responsible corporate citizenship and investment in the communities where they operate.

ANA is a launch customer and the biggest operator of the Boeing 787 Dreamliner, making ANAHD the biggest Dreamliner owner in the world. A member of Star Alliance since 1999, ANA has Joint Venture agreements with United Airlines, Lufthansa Airlines, Swiss International Airlines, Austrian Airlines and Brussels Airlines– giving it a truly global presence.

Supplementing its operations in commercial aviation, ANAHD has led the development of the innovative haptic robotics program, through its avatarin Inc. company, and its involvement in space with its partnership with JAXA, and other space related companies such as Astroscale and PD Aerospace.

The airline’s legacy of superior service has helped it earn SKYTRAX’s respected 5-Star rating every year since 2013, making ANA the only Japanese airline to win this prestigious designation and for eight consecutive years. ANA also has been recognized by Air Transport World as “Airline of the Year” three times (2007, 2013 and 2018); it is one of a select few airlines to win this prestigious award multiple times.

For more information, please refer to the following link:
https://www.ana.co.jp/group/en/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Caden Kinard, XPRIZE
caden.kinard@xprize.org

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 14:30:00 EEST | Press release

Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye